

[Asn¹⁰⁸] hTPO;
 [Asn¹¹⁷] hTPO;
 [Asn¹⁴⁷] hTPO;
 [Asn¹⁵³] hTPO;
 [Asn¹⁶⁴] hTPO;
 [Asn¹⁹³] hTPO;
 [Asn¹¹⁷, Asn¹⁴⁷] hTPO;
 [Asn¹¹⁷, Asn¹⁶⁴] hTPO;
 [Asn¹⁰⁸, Asn¹⁴⁷] hTPO;
 [Asn¹⁰⁸, Asn¹⁶⁴] hTPO;
 [Asn¹⁴⁷, Asn¹⁶⁴] hTPO;
 [Asn¹¹⁷, Asn¹⁴⁷, Asn¹⁶⁴] hTPO;
 [Asn¹⁰⁸, Asn¹⁴⁷, Asn¹⁶⁴] hTPO;
 [Asn¹⁰⁸, Asn¹¹⁷, Asn¹⁶⁴] hTPO;
 [Asn¹⁵⁷, Asn¹⁶⁴] hTPO;
 [Asn¹⁶², Ser¹⁶⁴] hTPO;
 [Asn¹⁶², Thr¹⁶⁴] hTPO;
 [Asn¹⁵³, Ser¹⁵⁵, Asn¹⁶⁴] hTPO;
 [Asn¹⁵³, Thr¹⁵⁵, Asn¹⁶⁴] hTPO;
 [Asn¹⁵⁹, Ser¹⁶¹, Asn¹⁶⁴] hTPO;
 [Asn¹⁵⁹, Thr¹⁶¹, Asn¹⁶⁴] hTPO;
 [Asn¹⁶⁶, Ser¹⁶⁸] hTPO;
 [Asn¹⁶⁶, Thr¹⁶⁸] hTPO; and
 [Asn¹⁶⁴, Asn¹⁶⁸] hTPO.

2. (UNCHANGED) The human thrombopoietin derivative of claim 1 which is [Asn¹⁶⁴] hTPO, [Asn¹⁹³] hTPO, [Asn¹⁰⁸, Asn¹¹⁷, Asn¹⁶⁴] hTPO, or [Asn¹⁵⁷, Asn¹⁶⁴] hTPO.

3. (AMENDED) A {R} recombinant gene encoding a human thrombopoietin derivative of claim 1.
 4. (AMENDED) A {R} recombinant gene encoding a human thrombopoietin derivative of claim 2.

A3
CONT.

5. (AMENDED) A {E}eukaryotic expression vector containing the recombinant gene of claim 3.

6. (UNCHANGED) The eukaryotic expression vector of claim 5 which is p40433, p40434, p40449, p40458, pD40433, pD40434, pD40449, or pD40458.

7. (UNCHANGED) Mammalian cell line CHO K-1/p40433 (Accession NO: KCTC 0495BP) transfected with the expression vector p40433 of claim 6.

8. (UNCHANGED) Mammalian cell line CHO dhfr-/pD40434 (Accession NO: KCTC 0630BP) transfected with the expression vector pD40434 of claim 6.

9. (UNCHANGED) Mammalian cell line CHO dhfr-/pD40449 (Accession NO: KCTC 0631BP) transfected with the expression vector pD0449 of claim 6.

10. (UNCHANGED) Mammalian cell line CHO dhfr-/pD40458 (Accession NO: KCTC 0632BP) transfected with the expression vector pD0458 of claim 6.

A4

11. (AMENDED) A {P}process of preparing {the} a human thrombopoietin derivative {of claim 1 wherein} comprising culturing a mammalian cell line containing the recombinant gene of claim 3 {is used to obtain the} and obtaining a human thrombopoietin derivative {of claim 1} from the cultured mammalian cell line.

12. (AMENDED) A {P}pharmaceutical composition containing the human thrombopoietin derivative of claim 1 {which is used for the treatment of thrombocytopenia}.

REMARKS

Applicants have amended claims 1, 3-5 and 11-12, as indicated above, to clarify the language of the claims. These amendments are supported by the original application as filed, and introduce no new matter.